Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Outcome of Micropulse Laser Transscleral Cyclophotocoagulation on Pediatric Versus Adult Glaucoma Patients

Lee, Jun, Hui*; Shi, Yuhua; Amoozgar, Behzad*; Aderman, Christopher*; De Alba Campomanes, Alejandra*; Lin, Shan*; Han, Ying*

doi: 10.1097/IJG.0000000000000757
Original Studies

Purpose: To study and compare the outcome of micropulse transscelral cyclophotocoagulation in pediatric glaucoma patients to that in adult glaucoma patients.

Methods: Consecutive pediatric and adult patients who received micropulse transscelral cyclophotocoagulation between July 2015 and December 2016 at University of California, San Francisco were retrospectively analyzed. All cases had at least 12 months of follow-up.

Results: Nine eyes from 9 pediatric patients and 27 eyes from 25 adult patients were included. The sample size in pediatric group is small because MP-TCP was not offered to pediatric patients after unsatisfactory results in initial cases. Preoperatively, the mean intraocular pressure (IOP) was 28.41±8.32 mm Hg in adult patients and 34.28±9.92 mm Hg in pediatric patients. Postoperatively, the mean IOP in adult patients significantly decreased at all follow-up points (P<0.001). In pediatric patients, the mean IOP decreased to 20.44±13.41 mm Hg at 1 month (P=0.021), 23.56±10.10 mm Hg at 3 months (P=0.093), 23.00±8.31 mm Hg (P=0.018) at 6 months, and 27.20±15.68 mm Hg (P=0.15) at 12 months. No significant complications were noted in either group. The success rate in adults was 72.22% versus 22.22% in pediatric patients at 12 months (P=0.02). Seven of 9 pediatric patients required reoperation during the 12 months of follow-up.

Conclusions: Micropulse transscelral cyclophotocoagulation is a safe procedure for pediatric as well as adult glaucoma patients. Its effect seems to be short lived in pediatric patients and the rate of reoperation was high.

*Department of Ophthalmology, University of California, San Francisco School of Medicine, San Francisco, CA

Department of Ophthalmology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China

J.H.L. and Y.S. contributed equally.

Supported by Research to Prevent Blindness. National Eye Institute, EY00216

Shan Lin is a consultant for Allergan (global headquarters in Dublin, Ireland and US Administrative Headquarters in Parsippany, NJ), Aerie Pharmaceuticals (Irvine, CA and Bedminster, NJ), and ALeyeGN Technologies, LLC (Los Altos, CA). Disclosure: The other authors have no conflict of interest to declare.

Reprints: Ying Han, MD, PhD, 10 Koret Street, K-323, P.O. Box 0730, San Francisco, CA 94143-0730 (e-mail: Ying.Han@ucsf.edu).

Received May 17, 2017

Accepted July 21, 2017

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.